Impact BioMedical Initiates Bioplastics Research Collaboration with One of World’s Largest Plastic Manufacturers
September 08 2020 - 08:00AM
Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE
American: DSS), a multinational company operating businesses
focusing on brand protection technology, blockchain security,
direct marketing, healthcare, real estate, and securitized digital
assets, today announced its wholly owned subsidiary Impact
BioMedical, Inc. (“Impact BioMedical”), through its subsidiary
Impact BioLife Science, Inc. (“Impact BioLife”), initiated a
bioplastics research collaboration with one of the world’s largest
plastic manufacturers. The collaboration is focused on developing
five new types of advanced microbial-resistant plastics.
The bioplastics research collaboration builds
upon existing research of Daryl Thompson, founder of advance
research company, GRDG Sciences, LLC. (“GRDG”), and Impact
BioLife’s Director of Scientific Initiatives. Notably, Thompson has
been twice nominated for the Nobel Prize for his work in
cutting-edge organic and carbohydrate chemistry.
“We are developing antimicrobial plastics for
consumer products that control the spread of active pathogens such
as SARS-CoV-2, Influenza, E. coli, Staph, and Rhinovirus,” stated
Thompson. “We are researching and exploiting key strategies found
in the biological realm that can create plastics that are highly
beneficial. Under this collaboration, we are specifically looking
at solutions for common products such as cups, plates, utensils,
plastic bags, and even counter tops, which together represent a
significant and timely market opportunity. We are targeting to
complete our research and testing phase early in the fourth
quarter, setting the stage to quickly move into negotiations for
global licensing and royalty agreements.”
GRDG is a specialized research team that focuses
on developing solutions for biodefense under the guidelines of the
Project BioShield Act, Event 201, and Potomac Institute for Policy
Studies.
GRDG performs rapid analysis and research by
using advanced algorithms and the most complete databases in the
world. The team operates in a lean and efficient manner and when
necessary utilizes the top contract research organizations to
deliver solid results that are robust and accurate.
GRDG’s Chief Scientific Advisor Dr. Roscoe M.
Moore, Jr., the former United States Assistant Surgeon General and
former Epidemic Intelligence Service Officer at Centers for Disease
Control and Prevention or CDC commented, “Research to date affirms
our belief that our bioplastics technology can be a major game
changer for a wide variety of consumer products and even
beyond.”
“Consumers have a newly heightened awareness of
the importance of microbial-resistant products and surfaces, and
the patented bioplastics we are developing could provide an
extremely effective solution to meet this growing unmet need,”
commented Jason Grady, Chief Operating Officer of DSS.
About Impact BioMedical,
Inc.Impact BioMedical, Inc. ("Impact BioMedical") is a
wholly owned subsidiary of DSS. Impact BioMedical strives to
leverage its scientific know-how and intellectual property rights
to provide solutions that have been plaguing the biomedical field
for decades. By tapping into the scientific expertise of GRDG
Sciences, LLC, Impact BioMedical pledges to undertake a concerted
effort in the R&D, drug discovery and development for the
prevention, inhibition, and treatment of neurological, oncological
and immuno related diseases. For more information on Impact
BioMedical visit http://impbio.com/.
About Document Security Systems, Inc.DSS is a
multinational company operating businesses focused on brand
protection technology, blockchain security, direct marketing,
healthcare, real estate, and securitized digital assets. Its
business model is based on a distribution sharing system in which
shareholders will receive shares in its subsidiaries as DSS
strategically spins them out into IPOs. Its historic business
revolves around counterfeit deterrent and authentication
technologies, smart packaging, and consumer product engagement. DSS
is led by its Chairman and largest shareholder, Mr. Fai Chan, a
highly successful global business veteran of more than 40 years
specializing in corporate transformation while managing risk. He
has successfully restructured more than 35 corporations with a
combined value of $25 billion.
For more information on DSS
visit http://www.dsssecure.com.
Investor Contact:
Dave Gentry, CEO RedChip Companies Inc. 407-491-4498
Dave@redchip.com
Safe Harbor Disclosure
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements include, but are not limited to,
statements related to the Company's intended use of proceeds and
other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are
subject to risks and uncertainties that may cause actual results or
events to differ materially from those projected. These risks and
uncertainties, many of which are beyond our control, include: risks
relating to our growth strategy; our ability to obtain, perform
under and maintain financing and strategic agreements and
relationships; risks relating to the results of development
activities; our ability to attract, integrate and retain key
personnel; our need for substantial additional funds; patent and
intellectual property matters; competition; as well as other risks
described in the section entitled "Risk Factors" in the prospectus
and in our other filings with the SEC, including, without
limitation, our reports on Forms 8-K and 10-Q, all of which can be
obtained on the SEC website at www.sec.gov. Readers are cautioned
not to place undue reliance on the forward-looking statements,
which speak only as of the date on which they are made and reflect
management's current estimates, projections, expectations and
beliefs. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by
law.
DSS (AMEX:DSS)
Historical Stock Chart
From Feb 2024 to Mar 2024
DSS (AMEX:DSS)
Historical Stock Chart
From Mar 2023 to Mar 2024